A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

305

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

July 9, 2026

Study Completion Date

December 9, 2026

Conditions

Psoriasis

Interventions

DRUG

HS-10374 6mg tablets

Administered orally QD for 12 weeks

DRUG

HS-10374-matched placebo tablets

Administered orally QD for 12 weeks

Trial Locations (1)

Shanghai Dermatology Hospital, Shanghai

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY